Skip to main content

NASDAQ:ARCT - Arcturus Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $70.67
  • Forecasted Upside: 143.51 %
  • Number of Analysts: 11
  • Breakdown:
  • 2 Sell Ratings
  • 5 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$29.02
▼ -2.78 (-8.74%)
1 month | 3 months | 12 months
Get New Arcturus Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARCT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARCT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$70.67
▲ +143.51% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Arcturus Therapeutics in the last 3 months. The average price target is $70.67, with a high forecast of $133.00 and a low forecast of $31.00. The average price target represents a 143.51% upside from the last price of $29.02.

Hold

The current consensus among 11 investment analysts is to hold stock in Arcturus Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
11/17/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
2/15/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
5/15/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 2 sell ratings
8/13/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 2 sell ratings
11/11/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 2 sell ratings
2/9/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 2 sell ratings
4/10/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 2 sell ratings
5/10/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/8/2021B. RileyLower Price TargetPositive ➝ Sell$45.00 ➝ $35.00Low
i
Rating by M. Mamtani at B. Riley
3/2/2021Roth CapitalLower Price TargetSell$77.00 ➝ $45.00Low
i
Rating by E. Piros at Roth Capital
2/17/2021B. RileyDowngradeNeutral ➝ SellLow
i
Rating by M. Mamtani at B. Riley
1/15/2021B. RileyDowngradeBuy ➝ Neutral$138.00 ➝ $77.00Medium
i
Rating by M. Mamtani at B. Riley
1/7/2021Wells Fargo & CompanyInitiated CoverageOverweight$118.00N/A
i
12/29/2020HC WainwrightDowngradeBuy ➝ Neutral$84.00 ➝ $50.00N/A
i
Rating by E. Arce at HC Wainwright
12/29/2020Robert W. BairdDowngradeOutperform ➝ Neutral$79.00 ➝ $69.00N/A
i
12/29/2020BarclaysDowngradeOverweight ➝ Equal Weight$68.00 ➝ $46.00N/A
i
12/29/2020Raymond JamesDowngradeOutperform ➝ Market Perform$46.00N/A
i
Rating by Steven Seedhouse at Raymond James
12/23/2020Roth CapitalDowngradeBuy ➝ Sell$77.00N/A
i
Rating by E. Pierce at Roth Capital
12/14/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target$62.00 ➝ $133.00Low
i
12/14/2020Smith Barney CitigroupBoost Price Target$62.00 ➝ $133.00Medium
i
12/7/2020B. RileyBoost Price TargetBuy$64.00 ➝ $111.00High
i
Rating by M. Mamtani at B. Riley
11/11/2020B. RileyLower Price TargetBuy$82.00 ➝ $64.00High
i
Rating by M. Mamtani at B. Riley
11/10/2020Raymond JamesLower Price TargetOutperform$79.00 ➝ $73.00High
i
Rating by Steven Seedhouse at Raymond James
10/26/2020BarclaysInitiated CoverageOverweight$72.00Medium
i
10/6/2020CitigroupInitiated CoverageBuy ➝ Buy$65.00High
i
8/25/2020Piper SandlerInitiated CoverageOverweight$77.00Medium
i
8/12/2020B. RileyBoost Price Target$70.00 ➝ $82.00Medium
i
Rating by M. Mamtani at B. Riley
8/11/2020Brookline Capital ManagementReiterated RatingBuyLow
i
Rating by K. Raja at Brookline Capital Management
8/11/2020Raymond JamesBoost Price TargetOutperform$72.00 ➝ $79.00High
i
Rating by Steven Seedhouse at Raymond James
8/11/2020HC WainwrightReiterated RatingBuy$78.00High
i
7/30/2020Roth CapitalInitiated CoverageBuy$77.00Medium
i
Rating by Y. Rahimi at Roth Capital
7/24/2020Raymond JamesReiterated RatingBuyHigh
i
Rating by Steven Seedhouse at Raymond James
7/24/2020HC WainwrightBoost Price TargetBuy$62.00 ➝ $78.00High
i
7/16/2020Raymond JamesInitiated CoverageOutperform$72.00Medium
i
7/12/2020B. RileyInitiated CoverageBuy$70.00High
i
Rating by Mayank Mamtani at B. Riley
6/9/2020WBB SecuritiesDowngradeBuy ➝ Hold$31.00Low
i
5/4/2020HC WainwrightReiterated RatingBuy$62.00Low
i
4/28/2020HC WainwrightBoost Price TargetBuy$26.00 ➝ $62.00High
i
4/14/2020HC WainwrightBoost Price TargetBuy$24.00 ➝ $26.00High
i
3/18/2020Robert W. BairdReiterated RatingBuy$26.00High
i
Rating by Madhu Kumar at Robert W. Baird
3/12/2020HC WainwrightBoost Price TargetBuy$18.00 ➝ $24.00High
i
3/5/2020LADENBURG THALM/SH SHBoost Price Target$22.00 ➝ $28.00High
i
3/4/2020HC WainwrightReiterated RatingBuy$18.00High
i
3/4/2020Roth CapitalBoost Price TargetBuy$14.00 ➝ $24.00High
i
Rating by Y. Rahimi at Roth Capital
2/10/2020Robert W. BairdInitiated CoverageOutperform$24.00High
i
2/6/2020GuggenheimInitiated CoverageBuy$19.00High
i
1/9/2020HC WainwrightReiterated RatingBuy$18.00Low
i
Rating by Ed Arce at HC Wainwright
8/16/2019HC WainwrightSet Price TargetBuy$18.00High
i
Rating by Ed Arce at HC Wainwright
8/7/2019HC WainwrightBoost Price TargetBuy$16.00 ➝ $18.00Medium
i
Rating by E. Arce at HC Wainwright
7/24/2019Brookline Capital ManagementReiterated RatingBuyHigh
i
Rating by K. Raja at Brookline Capital Management
6/20/2019Chardan CapitalSet Price TargetBuy$18.00High
i
Rating by Keay Nakae at Chardan Capital
4/5/2019HC WainwrightInitiated CoverageBuy ➝ Buy$15.00Low
i
Rating by E. Arce at HC Wainwright
3/19/2019Chardan CapitalReiterated RatingBuy$18.00Medium
i
Rating by K. Nakae at Chardan Capital
2/20/2019Roth CapitalReiterated RatingBuyMedium
i
Rating by Y. Rahimi at Roth Capital
2/19/2019LaidlawInitiated CoverageBuyLow
i
9/27/2018Brookline Capital ManagementReiterated RatingBuyLow
i
Rating by K. Raja at Brookline Capital Management
9/20/2018WBB SecuritiesUpgradeBuy ➝ Strong-BuyLow
i
6/11/2018WBB SecuritiesUpgradeHold ➝ BuyMedium
i
5/31/2018LADENBURG THALM/SH SHUpgradeNeutral ➝ BuyHigh
i
Rating by Wangzhi Li at LADENBURG THALM/SH SH
2/28/2018LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralLow
i
1/22/2018Chardan CapitalInitiated CoverageBuy ➝ Buy$12.00High
i
Rating by K. Nakae at Chardan Capital
11/29/2017LADENBURG THALM/SH SHInitiated CoverageBuy ➝ BuyHigh
i
10/9/2017WBB SecuritiesUpgradeHold ➝ Buy$2.00N/A
i
9/29/2017Roth CapitalDowngradeBuy ➝ Neutral$4.00 ➝ $1.00Low
i
Rating by Michael Higgins at Roth Capital
6/12/2017Jefferies Financial GroupReiterated RatingHold$1.25Low
i
5/31/2017Roth CapitalSet Price TargetBuy$4.00High
i
Rating by Michael Higgins at Roth Capital
4/13/2017Cantor FitzgeraldReiterated RatingHold$1.00Low
i
Rating by Mara Goldstein at Cantor Fitzgerald
3/31/2017Jefferies Financial GroupReiterated RatingHold$1.25Low
i
3/28/2017Cantor FitzgeraldReiterated RatingHold$1.00Low
i
Rating by Mara Goldstein at Cantor Fitzgerald
2/9/2017Roth CapitalUpgradeNeutral ➝ Buy$4.00N/A
i
Rating by M. Higgins at Roth Capital
1/18/2017Jefferies Financial GroupDowngradeBuy ➝ Hold$6.00 ➝ $1.25N/A
i
1/17/2017Roth CapitalDowngradeBuy ➝ Neutral$1.00N/A
i
Rating by M. Higgins at Roth Capital
1/17/2017Cantor FitzgeraldSet Price TargetHold$2.00N/A
i
Rating by Mara Goldstein at Cantor Fitzgerald
1/17/2017Stifel NicolausSet Price TargetHold$2.00N/A
i
Rating by Thomas Shrader at Stifel Nicolaus
1/17/2017OppenheimerReiterated RatingHoldN/A
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
1/17/2017Piper Jaffray CompaniesSet Price TargetHold$3.00 ➝ $2.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
11/16/2016Jefferies Financial GroupReiterated RatingBuy$6.00N/A
i
11/2/2016WBB SecuritiesUpgradeSell ➝ Hold$4.00 ➝ $1.90N/A
i
10/28/2016BarclaysDowngradeEqual Weight ➝ Underweight$3.00 ➝ $2.00N/A
i
10/7/2016Stifel NicolausDowngradeBuy ➝ HoldN/A
i
10/3/2016Jefferies Financial GroupReiterated RatingBuy$9.00 ➝ $6.00N/A
i
10/1/2016Roth CapitalSet Price TargetBuy$8.00N/A
i
Rating by Michael Higgins at Roth Capital
9/29/2016Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$10.00 ➝ $3.00N/A
i
9/29/2016OppenheimerDowngradeOutperform ➝ Market PerformN/A
i
9/29/2016Cantor FitzgeraldDowngradeBuy ➝ Hold$2.00N/A
i
Rating by Mara Goldstein at Cantor Fitzgerald
9/29/2016Cantor FitzgeraldReiterated RatingBuy ➝ Buy$16.00N/A
i
Rating by Mara Goldstein at Cantor Fitzgerald
9/12/2016WBB SecuritiesDowngradeHold ➝ Sell$5.00 ➝ $4.00N/A
i
9/1/2016The Goldman Sachs GroupReiterated RatingBuyN/A
i
8/31/2016Cantor FitzgeraldReiterated RatingBuy$16.00N/A
i
Rating by Mara Goldstein at Cantor Fitzgerald
8/30/2016Piper Jaffray CompaniesReiterated RatingOverweight$10.00N/A
i
8/25/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
8/1/2016BarclaysInitiated CoverageEqual Weight$8.00N/A
i
6/21/2016Roth CapitalReiterated RatingBuy$12.00N/A
i
Rating by M. Higgins at Roth Capital
6/7/2016Canaccord GenuityInitiated CoverageBuyN/A
i
6/7/2016Cantor FitzgeraldInitiated CoverageBuy$16.00N/A
i
(Data available from 5/10/2016 forward)
Arcturus Therapeutics logo
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Its preclinical drug discovery and development programs include LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 209 patents and patent applications, issued in the United States and other countries. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection; CureVac AG to develop mRNA therapeutic and vaccine candidates; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $29.02
$28.97
$30.93

50 Day Range

MA: $39.23
$30.15
$48.34

52 Week Range

Now: $29.02
$28.92
$129.71

Volume

28,298 shs

Average Volume

1,084,262 shs

Market Capitalization

$763.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.01

Frequently Asked Questions

What sell-side analysts currently cover shares of Arcturus Therapeutics?

The following Wall Street research analysts have issued research reports on Arcturus Therapeutics in the last twelve months: B. Riley, Barclays PLC, Brookline Capital Management, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, HC Wainwright, Piper Sandler, Raymond James, Robert W. Baird, Roth Capital, Smith Barney Citigroup, WBB Securities, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for ARCT.

What is the current price target for Arcturus Therapeutics?

12 Wall Street analysts have set twelve-month price targets for Arcturus Therapeutics in the last year. Their average twelve-month price target is $70.67, suggesting a possible upside of 143.5%. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell has the highest price target set, predicting ARCT will reach $133.00 in the next twelve months. WBB Securities has the lowest price target set, forecasting a price of $31.00 for Arcturus Therapeutics in the next year.
View the latest price targets for ARCT.

What is the current consensus analyst rating for Arcturus Therapeutics?

Arcturus Therapeutics currently has 2 sell ratings, 5 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ARCT, but not buy more shares or sell existing shares.
View the latest ratings for ARCT.

What other companies compete with Arcturus Therapeutics?

How do I contact Arcturus Therapeutics' investor relations team?

Arcturus Therapeutics' physical mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company's listed phone number is 858-900-2660 and its investor relations email address is [email protected] The official website for Arcturus Therapeutics is www.arcturusrx.com.